Clinical trial

Dexamethasone and Ondansetron Hydrochloride or Palonosetron Hydrochloride in…

NCT00343863 · University of Washington, Other · Completed

Key facts

NCT number NCT00343863
Title Dexamethasone and Ondansetron Hydrochloride or Palonosetron Hydrochloride in Preventing Nausea and Vomiting in Patients Receiving Doxorubicin Hydrochloride and Cyclophosphamide For Early Stage Breast Cancer
Official title Efficacy of Palonosetron in the Prevention of Acute and Delayed Chemotherapy-Induced Nausea and Vomiting Following Dose Dense Adriamycin-Cyclophosphamide Chemotherapy in Early Stage Breast Cancer Patients
Lead sponsor University of Washington, Other
Collaborators National Cancer Institute (NCI) NIH
Status Completed
Study type Interventional
Conditions Male Breast Cancer, Nausea and Vomiting, Stage I Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer
Intervention type Drug, Other, Procedure
Interventions palonosetron hydrochloride, cyclophosphamide, dexamethasone, doxorubicin hydrochloride, quality-of-life assessment, nausea and vomiting therapy, management of therapy complications, ondansetron hydrochloride, survey administration
Enrollment 41
Start date Jan 1, 2006
Primary completion Dec 1, 2010
Completion Dec 1, 2010
First posted Jun 23, 2006
Last update posted Jul 11, 2017
Countries United States

At a glance

  • 1–9 Study sites
  • Yes Results posted
  • None Linked FDA submissions

Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.

About ClinicalTrials.gov studies

ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.

Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date:

Browse all ClinicalTrials.gov studies